High levels of triglycerides, a type of fat found in the blood, have been connected to an increased risk of cardiovascular diseases. The question of whether decreasing these levels can reduce the incidence of cardiovascular events has been under investigation. Pemafibrate, a selective peroxisome proliferator–activated receptor α modulator, has been shown to lower triglyceride levels […]
Category: Cardiovascular Disease
A New Frontier in Heart Failure Management: A Comprehensive Review of Landmark Clinical Trials on SGLT2 Inhibitors
Explore the transformative clinical trials that have solidified the role of SGLT2 inhibitors in heart failure management and their potential to redefine the treatment landscape. Introduction Heart failure is a complex clinical syndrome associated with significant morbidity and mortality. In recent years, sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a promising new class of drugs […]
Navigating the New Era: Landmark Clinical Trials on Eliquis (Apixaban) for Anticoagulation in Atrial Fibrillation
Atrial fibrillation (AFib) is a prevalent cardiac arrhythmia that significantly elevates the risk of stroke and systemic embolism. As a result, effective anticoagulation therapy is crucial for managing AFib patients. Over the past decade, novel oral anticoagulants (NOACs) have challenged traditional vitamin K antagonists, like warfarin, as preferred therapeutic options. Eliquis (apixaban) is one such […]
Pioneering the Path: Key Landmark Trials on Ablation Procedures for Atrial Fibrillation
Delve into the pivotal clinical trials that have shaped our understanding and management of atrial fibrillation through ablation procedures.
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent form of heart failure, accounting for nearly half of all heart failure cases. Despite its significance, HFpEF remains a challenging condition to manage and treat, as effective therapies have been limited. In this article, we delve into the landmark clinical trials that […]
APAF Trial: Ablation or Antiarrhythmics for PAF
2006 APAF STUDY A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation (AF) randomized controlled trial M Objective: To compare the relative efficacy of circumferential pulmonary vein ablation (CPVA) & antiarrhythmic drug therapy (ADT) in the treatment of patients with paroxysmal atrial fibrillation (PAF) who have already […]
ANTHARTIC Trial: Preventing VAP after CA
2019 ANTHARTIC TRIAL M Prevention of early Ventilator-Associated Pneumonia after cardiac arrest Multicentre, randomised, double-blind, placebo-controlled Objective: To investigate whether in post out-of-hospital cardiac arrest (OOHCA) patients treated with targeted temperature management, does the use of empirical antibiotics prevent early ventilator-associated pneumonia. 194 patients Inclusion criteria: Patients ≥ 18 years of age hospitalized in the […]
ANT 005 TKA Trial: Abelacimab for VTE
2021 ANT-005 TKA TRIAL M Abelacimab for Prevention of Venous Thromboembolism (VTE) Phase 2,open-label, prospective randomized trial 400 Objective: To compare the efficacy & safety of abelacimab administered postoperatively with the efficacy & safety of enoxaparin in patients undergoing total knee arthroplasty. patients Inclusion criteria: Patients 18 to 80 years of age undergoing elective […]
Amulet IDE Trial: Amulet LAA closure device vs. Watchman for Stroke ppx
2021 AMULET IDE TRIAL Amplatzer Amulet left atrial appendage occluder versus watchman device for stroke prophylaxis multicenter, open label, prospective, randomized controlled trial M Objective: To evaluate the safety & effectiveness of the dual-seal mechanism of the Amulet left atrial appendage occluder compared with the Watchman device among patients with nonvalvular atrial fibrillation (AF) 1878 […]
AMPLITUDE-O Trial: CV and Renal Outcomes with Efpeglenatide
2021 AMPLITUDE-O TRIAL M Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes international, randomized, controlled trial Objective: To evaluate efpeglenatide in participants with type 2 diabetes and either a history of cardiovascular disease or current kidney disease 4076 patients Inclusion criteria: Participants ≥18 years of age with type 2 diabetes mellitus and history […]